Picture supply: Getty Pictures
In the beginning of the yr, I made a decision I’d keep away from doubling down on my dropping ISA investments. In different phrases, these holdings in my Shares and Shares ISA that had taken a giant plunge.
Particularly, I had been lower by a few falling knives known as Diageo and Moderna. My technique was to return to backing confirmed winners and corporations on an upwards trajectory.
However 4 months into the yr, I’ve simply damaged this plan. How so? Properly, I added to my holding in healthcare large Novo Nordisk (NYSE: NVO), which had fallen 60% in 10 months.
Right here, I’ll clarify why.
A still-growing enterprise
Returning to Diageo and Moderna, these have been corporations I assumed had thrilling long-term futures (in premium spirits and mRNA expertise respectively).
Nonetheless, their near-term prospects regarded cloudy, with weakening gross sales. Consequently, there was loads of pessimism surrounding the pair, which I assumed was overdone. However I underestimated the severity of their operational challenges and each shares stored falling decrease after I doubled down.
In contrast, Novo Nordisk is a pacesetter in diabetes and GLP-1 weight-loss medicines — two areas which might be nonetheless rising strongly. This yr, the corporate’s income is predicted to extend 18% to round $52bn, with an analogous rise in earnings per share.
Trying additional forward, forecasts have income topping $70bn by 2028. Due to this fact, this doesn’t look like an organization whose development trajectory is in any actual peril.
So why on earth did the inventory plunge 60% inside one yr?
Rising competitors
The chief offender is Eli Lilly, the corporate’s arch-rival within the profitable GLP-1 weight-loss remedy house. Whereas Novo Nordisk presently holds a market-leading place by way of its blockbuster injectable medicine Wegovy and Ozempic, Eli Lilly is profitable the race to commercialise a each day weight-loss capsule.
Briefly then, the market’s fearful about rising competitors. This largely explains why the inventory has crashed, although uncertainty round tariffs additionally continues to weigh on the general pharmaceutical sector.
Turning to telehealth platforms
To shore up its market place within the right here and now, Novo not too long ago signed offers with US digital well being suppliers to promote Wegovy at discounted costs by way of their platforms.
In the meantime, Novo Nordisk is promoting the remedy at beginning costs of $499 a month by itself direct-to-consumer on-line pharmacy (NovoCare). This could assist hold gross sales excessive, although margins might take a little bit of a success because of the discounted costs.
Enticing valuation
The inventory’s risen practically 10% since I broke my ISA vow and topped up at $60. Nonetheless, it’s nonetheless buying and selling at simply 14 instances forecast earnings for 2026. That appears very low cost to me, regardless of the rising aggressive menace from Eli Lilly.
In keeping with forecasts from the World Weight problems Federation, the variety of overweight adults will hit round 1.53bn by 2035. So the addressable market right here is just huge. This might see gross sales of GLP-1 medicine for kind 2 diabetes and weight problems rise above $150bn within the 2030s, up from round $50bn final yr. And experiences say these remedies are lastly set to be advisable by the World Well being Organisation (WHO) in August.
Reality is, it’s unlikely Eli Lilly will completely nook this large market. So I see Novo Nordisk inventory as an affordable approach for me to speculate on this international mega-trend.
